Erin Crown, PA
Physician Assistant · State College, PANPI 1831535780
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $791,527 of the $1,239,691 with a category attached, or 63.8%. 31 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 31.9% of the total. 2025 is the largest year on record at $362,228, more than ten times the $20,248 reported in 2021. Among physician assistant clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,461 payments — averaging $503.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$395K
- Otsuka America Pharmaceutical, Inc.$270K
- Johnson & Johnson$209K
- Axsome Therapeutics, Inc.$147K
- Neurocrine Biosciences, Inc.$89K
- E.r. Squibb & Sons, L.L.C.$78K
- plus $51K from 25 others
Across 21 payments — averaging $14,667 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$300K
- Boehringer Ingelheim RCV GmbH & Co KG$5K
- Boehringer Ingelheim International GmbH$4K
What the payments were for
- Consulting fees$181,81015%
- Speaking & faculty fees$791,52764%
- Travel & lodging$222,39918%
- Food & beverage$43,9084%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 645 | $395,467 |
| Otsuka America Pharmaceutical, Inc. | 657 | $269,961 |
| Johnson & Johnson | 399 | $208,687 |
| Axsome Therapeutics, Inc. | 220 | $147,002 |
| Neurocrine Biosciences, Inc. | 130 | $89,285 |
| E.r. Squibb & Sons, L.L.C. | 101 | $78,199 |
| Supernus Pharmaceuticals, Inc. | 80 | $21,247 |
| H. Lundbeck A S | 5 | $10,088 |
| Janssen Scientific Affairs, LLC | 4 | $4,840 |
| Janssen Global Services, LLC | 8 | $4,781 |
| Lundbeck LLC | 30 | $3,742 |
| AbbVie | 71 | $2,359 |
| Boehringer Ingelheim | 2 | $1,079 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $961 |
| Alkermes, Inc. | 15 | $462 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $318 |
| Ironshore Pharmaceuticals Inc. | 16 | $244 |
| Collegium Pharmaceutical, Inc. | 12 | $172 |
| Sage Therapeutics, LLC | 2 | $163 |
| Teva Pharmaceuticals USA, Inc. | 8 | $145 |
| Sunovion Pharmaceuticals Inc. | 8 | $118 |
| Merck | 6 | $112 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
| Indivior Inc. | 2 | $46 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Eisai Inc. | 2 | $34 |
| Novo Nordisk | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Braintree Laboratories, Inc. | 1 | $14 |
| Corium, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$386,931
- SPRAVATO$153,784
- Auvelity$142,828
- ABILIFY MAINTENA$136,325
- REXULTI$131,961
- INGREZZA$86,820
- ABILIFY ASIMTUFII$63,306
- INVEGA SUSTENNA$59,017
- INVEGA TRINZA$58,071
- COBENFY$36,338
- QELBREE$20,302
- ARISTADA$833
- VRAYLAR$750
- TRINTELLIX$625
- INVEGA$267
- LYBALVI$208
- Sotyktu$111
How this compares
$1,239,691 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify AsimtufiiAripiprazole | 31 | $175,280 |
| Abilify MaintenaAripiprazole | 26 | $66,808 |
| Invega SustennaPaliperidone Palmitate | 18 | $62,664 |
| CaplytaLumateperone Tosylate | 24 | $38,456 |
| VraylarCariprazine Hcl | 15 | $21,430 |
| Aripiprazole | 86 | $11,370 |
| TrintellixVortioxetine Hydrobromide | 11 | $4,955 |
| Duloxetine Hcl | 57 | $3,867 |
| Bupropion XlBupropion Hcl | 94 | $2,859 |
| Quetiapine Fumarate | 54 | $2,485 |
| Prazosin Hcl | 39 | $2,015 |
| Paliperidone ErPaliperidone | 27 | $1,914 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 84 | $1,666 |
| Hydroxyzine Hcl | 107 | $1,550 |
| Divalproex Sodium | 18 | $1,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Abilify Maintena | $269,961 | $242,08957 claims |
| Johnson & JohnsonInvega Sustenna | $208,687 | $62,66418 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $395,467 | $38,45624 claims |
| AbbVieVraylar | $2,359 | $21,43015 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $961 | $4,95511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in State College
- Sarah WestinState College$16K
- Tricia BootsCranberry Twp$313K
- Melissa FerrariPhiladelphia$223K
- Jason OberdickWexford$206K
- Justine RobertsMurrysville$173K
- Allison BoydErie$163K
- Joshua TrbovichWashington$144K
- Daniel TelegaErie$124K
- Jeffrey CameronWashington$89K
- Dorissa BrivchikPittsburgh$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.